ectual Property Organi

(43) International Publication D: 16 May 2002 (16.05.2002)

PCT


WO 02/38207 A1

- (51) International Preset Chesification¹: A61M 15/00. (73) 8053 1100 (75)
- den Number: PCT/GB01/04964
- (25) Filing Language:
- (20) Publication Languages
- (30) Priority Date: 00310049.2 13 November 2000 (13.11.2000) EP
- (71) Applicant (for all desponsed Same energy LCS; THE (84) Designated Same (regional); ARIFO patrix (CH TECHNOLOCY PARTNERSHIP FLC (CB/CB);
 McDawres Science Fact, Contridge Road, McDawra,
 McDawres Science Fact, Contridge Road, McDawra, in SCH SER (CB)
- un (for LS only): POLLOCK, Nes contestado, Royanos, Herro SGS TOR
- (74) Agusto GDLL JERNIENCS & EVERY; Bu 7 Eldon Street, London BCZM 7LH (GB).
- Designated STates (seafered): A.R. A.G. A.H. A.M. A.T. A.H. A.Z. Du. B.B. B.G. Du. B.Y. B.Z. C.A. C.H. C.M. C.G. C.H. C.D. Do. D.C. Du. M.D. Z.E. C.E. B.S. P. D.G. G.D. G.G. G.M. (R.H. D. D. I. D. N. B. P.E.I. G.J. D.P. D.E. Z. L.C. L. L. I.S. I. Z. L. L.H. J. H. A. B.D. B.G. L. B.Z. L. C. L. L. I.S. S. Z. L. L. Y. H. A. B.D. B.G. L. B.K. B.W. B.W. B.Z. N.S. N.S. R.G. G.M. P.F. P.P. B.G. B.H. S.G. G.N. G.S. S.S. S. S. T.R. T.B. T.R. T.T. T.Z. U.R. U.G. U.S. U.Z. V.N. Y.H. Z. A. Z.W.
 - potent (AM, AZ, BY, KG, KZ, MD, KL, TJ, 1 ML, DAVIDA potent (AT, BB, CH, CY, DB, DK, ES, FI, FR, GB, GR, EB,

[Continued on next page]

(54) This: AEROSOL DRUG-DISPENSING WITH MEMBRANE FOR CONTROLLING VACUUM DURING DISPENSING

English



struct: An acrosol drug-dispassing device (25) psovides of dose of a pharmacentoologically active liquid (7) to a reservoir (18), which includes a perform quantitrum (16) achda s pe holding reservoir (11), which includes a performs membrane (a from which the dome in depensed on an extensed grow, The flow which the dome in depensed on an extensed grow, The suches in the force of a recilitier disapping (15) which has a mean surface in the force of a recilitier disapping (15) which is seen able to very the volume of, and thus adjust the pressure is, chamber(72) to provide a pressure difficiential scross the reali-displangs (13) during scientists of the performs encethency to such that the pressure which the bolding scenarior (16) is last in the subsists pressure on the opposite side of the performs ence-tracting of the resilient sightwaps (15) and thus the general structing of the resilient sightwaps (15) and thus the general of the difficulty pleasure scross the performs membranes of

PCT/GB01/04964 WO 02/38207

ARROSOL DEGG-DISPRESING WITH MEMBRANE FOR CONTROLLING VACUUM DURING DISPENSING

This invention relates to aerosol drug dispensing devices and, in particular, to those devices in which pharmacologically active liquid is provided to a holding reservoir from which the dose is then dispensed as an aerosol spray.

Prior known aerosol drug dispensing devices have used a number of different means for creating a negative pressure behind a perforate membrane which acts as part of a sorey head. In order that a dose of pharmacologically active liquid can be dispensed as a spray, the perforate membrane must be actuated to cause liquid flow though the perforate membrane.

Previously, the perforate membrane has been actuated by vibrating means and the pressure on the liquid side of the perforate membrane altered by means such as a pump or an expanding syringe mechanism. These methods have proved to be complex and the devices are difficult to manufacture.

Our earlier international patent application, WO95/15822, discloses a dispensing apparatus having a perforate membrane through which droplets are dispensed. The perforate membrane is provided with a number of perforations having a reverse taper, namely a larger cross-sectional area at that face of the membrane away from which Squid droplets emerge than at the opposite tace of the membrane, from which opposite face siguid flows in use to replace that in the emerging droplet spray.

The present invention aims to overcome the above problems.

According to the present invention, there is provided an serosol drug dispensing device in which a metered dose of a pharmacologically active liquid is provided to a holding reservoir from which the dose is then dispersed as an aerosol spray, the holding received including a perforate membrane from which the dose is dispensed by actuation of the perforate membrane to cause liquid flow through the perforate membrane, the perforate membrane having perforations having a reverse taper, namely a larger crosssectional area at that face of the membrane away from which figuid droplets emerge then at the opposite face of the membrane, characterised in that:

the holding reservoir is disposed in a chamber having a movable surface in the form of a resilient diaphragm which is stretchable to vary the volume of, and thus adjust the pressure in, the chamber to provide a pressure differential across the resident dispirages during actuation of the perforate membrane such that the pressure within the holding reservoir is less than the ambient pressure on the opposite side of the perforate

a control device is emanged to control the stretching of the resident disphragm and thus the generation of the differential pressure across the perforate membrane.

TT, LU, MC, KL, PT, SE, TR), CAPI prices (BE, BL, CP, CU, CL, CL, CM, GA, GPL OQ, GW, ML, MR, MR, SR, TD,

15

WO 02/38207

In this way, the differential pressure can simply and accurately be controlled such that the required pressure differential is easily maintained.

Preferably, the resilient diaphragm is formed from an elastomeric material such as rubber.

Preferably, the chamber contains one or more valves for controlling the inlet andler outlet of fixeds from the chamber

· The control device may be a raciproceting plunger which is connected to the resilient diaphragm substantially at the centre.

Preferably, the resilient disphragm is clamped by a spray head assembly substantially at its outer edge. Sealing means such as an O-ring may be provided to ensure no fluid flows past the resilient diaphragm.

An embodiment of the present invention will now be described with reference to the accompanying drawings, in which:

Fig. 1 shows a cross sectional side view of a device according to the present invention;

Figs. 2 to 6 show successive stages during operation of the device of Fig. 1;

Fig. 7 shows a trigger circuit for controlling the dispensing of the pharmacologically active liquid; and

Figs. 8a and 8b illustrate, in section, preferred forms of the perforate membrane for the device of Fig. 1.

As can be seen from Figs. 1 to 6, a drug dispensing device 25 forming part of a drug delivery system has a hollow casing 1 in which a reservoir body 2 is slidably mounted. A seray head mounting assembly 3 is attached to one end of the casing 1, the mounting assembly 3 comprising spray head assembly 3a, clamping means 4, disphragm clamp 11a and seal 17. A main return spring 5 is provided between a recess... 29 in the casing 1 and the reservoir body 2 to support the reservoir body 2, biassed towards its topmost position (as shown), within the casing 1. The reservoir body 2 is movable between a first and second position within the casing 1.

The reservoir body 2 has a reservoir cavity 6 in which a liquid drug 7 is stored and which can be increed-up via a re-fill port Z3. A plunger 8 is provided within the reservoir body 2 and extends out of the upper (as shown in the figures) end of the reservoir body 2, such that it engages with a cap 9 which covers the top of the device 25. A plunger return spring 10 is provided which extends from the reservoir body 2 and biases the plunger B out of the reservoir cavity 6.

A metering cavity 12 is provided at the lower end of the reservoir cavity 6 and the metering cavity 12 is in figuid communication, via a one-way ball valve 13, with a dispensing conduit or tube 14 provided within the lower end of the reservoir body 2. An

15

WO 02/38297

10

35

PCT/GB01/01964

elastomenic diaphragm 15 is provided around the lower portion of the reservoir body 2 and is joined at its outer edge to the cashing 1 by diaphragm clamp 11e and a seet 11, which is an O-ring, to define, together with the reservoir body 2 and the cashing 1, a chamber V1.

The spray head mounting assembly 3 is provided with an outlet 26 covered by a membrane 16 which, together with the lower portion of the reservoir body 2, the spray head mounting assembly 3 and the elastomeric disphragan 15, defines a chamber V2. The membrane 16 is retained by a seal 17 and is provided with a perforate portion 27 over which a holding reservoir 18 is provided and which can receive liquid drug 7 through the dispensing conduit or tube 14 in use. The perforate portion 27 of the membrane 16 has perforations 50 (see Figs. 8a and 8b) of a reverse taper and this is described in greater detail with reference to Figs 8a and 8b.

The sprey head mounting assembly 3 is provided with a damping intervelve 19

- teading into the chamber V1, a first one-way exhaust velve 20 from the chamber V1 and a second one-way exhaust valve 21 from the chamber V2.

Fig. 1 shows the device 25 at rest prior to metering a prodefuned dose of drug 7 into the holding reservoir 18. In this state, both the main return spring 5 and the plunger return spring 10 are extended so that the reservoir body 2 and the plunger 8 have been pushed fully ultiwards against physical stops (not shown).

The elastomenic disphragm 15 is stretched from its normally fad state and acts as a flexible wall, separating the two chambers V1 and V2. These chambers are initially at ambient pressure and the perforations 50 in the perforate portion 27 of membrane 16 are dry and open.

The operation of the device shown in Fig. 1 will now be described with reference 25 to Figs. 2 to 6.

To initiate operation of the device 25, the cap 9 is pressed downwards 9a (see Fig. 2). The reservoir body 2 and the plumper 8 are moved downwards at approximately the same rate, compressing the main return spring 5 until the reservoir body 2 reaches physical stops 28. At this stage the force exerted on the plumper return spring 10 is less than its preloted. The lower end of the dispersing conduit or tube 14 is now positioned close to the timer surface of the membrane 16.

The reservoir body 2 forms an air-light skiling seal with the casing 1. Therefore, as the reservoir body 2 descends, air is displaced from the chamber V1, through the first one-way exhaust valve 20 and the elastomeric diaphregm 15 returns towards its retaxed, almost first state. At the same time, air is displaced from the chamber V2 through the second one-way exhaust valve 21, through the damping valve 19, and through the perforate portion 27 of the membrane 16.

3

79/D 02/02207 PCT/GB01/04964

pressures generated in the chambers V1, V2 and by tension in the elastomeric discharge 15.

However, when the damping valve 19 is slightly open, it will allow air to enter into, and conversely exhaust from, the chamber V1 at a rate determined by the restoring force of the main return spring 5. Therefore, as the main return apring 5 pushes the reservoir body 2 upwards 2a, the volume of chamber V1 expands at a controlled rate until the reservoir body 2 reaches a practitined physical stop (not shown) (see Fig. 6).

The main return spring 5 also causes the elastoments disphragm 15 to stretch at a controlled rate which, in turn, causes the volume of the chamber V2 to expand at a controlled rate. The pressure within the chamber V2 behind the spray head assembly 3a therefore reduces at a controlled rate.

The physical stop (not shown) for the upward movement of the reservoir body
2 thitis the extension of the stretched etastomenic disphragm 15 and defines the final
volume change of the chamber V2 and thus the target negative pressure achieved in V2.

At this stage, the pressure in the chamber V1 is at ambient pressure.

Therefore, the net result is that the target (operating) negative pressure, which is close to the bubble point pressure for the spray head assembly 3s (the bubble point pressure being the pressure differential at which air bubbles enter the chamber V2 through the perforations 50 in the perforate portion 27, by overcoming the surfaces the mention of the mention of the dual drug), can be reached at a controlled rate without air being injected through the membrane 16.

If the negative pressure in the chamber V2 is generated too quickly, i.e. by opening the damping velve 19 too far, then the surface tension of the liquid drug covering the perforations in the perforate portion 27 of the membrane 16 will be overcome. Air will then be ingested rapidly through the perforate portion 27, hence cancelling the negative pressure in the chamber V2. In the absence of a negative pressure, the drug dispersing device 25 will not generate a spray.

It should be noted that the rate of air admission and exhaustion through damping valve 19 is much less than the rate of exhaustion through the first one way exhaust valve 20

An electronic control circuit 90 as shown in Fig. 7 triggers the delivery of the liquid drug through the perforate portion 27 of the membrane 18 by controlling membrane actuating means (not shown) such as plezoelectrically activated vibrating means. The control system uses a small holl wise enemometer 39 to monitor air flow into the drug delivery system. The anomatter 39 senses when a potient is infuling and bying to tripoer the pray head delivery.

As can be seen in Fig. 3, once the reservoir body 2 has reached its physical stops 28, further depression of the cap 9 compresses the plunger return spring 10. This pushes 8a the plunger 8 into the metering cavity 12 (see Fig. 1). The plunger 8 is provided with a plunger set 24 which engages with the side wall 12a of the metering carvity 12 to form a seal therowith. This traps a metered dose of the leguid drug 7 in the metering carvity 12. The sealing pressure of the plunger seal 24 against the side-wall 12a of the metering carvity 12 is greater than the sealing pressure of the etastomenic ball valve 13 against the ball valve seat 13a. Therefore, as the plunger 8 is depressed further, the trapped dose of liquid drug 7 is displaced from the metering carvity 12 past 13b the one-way elastomenic bell valve 13, through the dispensing conduit or tube 14 and into the holding reservoir 18. The holding reservoir 18 has a side-vall 22 which is either coatted with or formed of PTFE. In this configuration, all of the perforations 50 in the perforate portion 27 of membrane 16 are now covered with liquid drug 7a.

Once the cap 9 is released, as shown in Fig. 4, the plunger return spring 10 starts to expand, pushing 8b the plunger 8 out of the metering cavity 12, thus creating a partial vacuum in the metering cavity 12. The elastometric bell valve 13 remains closed. The plunger return spring 10 is strong enough to overcome this partial vacuum so as to push 8b the plunger 8 clear of the metaring cavity 12 until it reaches e physical stop (not shown). This partial vacuum pressure reduces as the plunger 8 is withdrawn 8b from the metering cavity 12 until the pressure drop across the plunger seal 24 exceeds the scaling pressure against the side-wall 12a of the metering cavity 12. A small amount of liquid drug 7 can then flow past the plunger seal 24 into the metering cavity 12 as the plunger 8 is withdrawn 8b. The main return spring 6 is able to extend, pushing 2a the reservoir body 2 upwards as shown in Fig. 5. This then causes the chambers V1 and V2 to expand and the electomeric disphragm 15 to stretch.

Air cannot enter through the one-way valves 20, 21 or through the perforate portion 27 of membrane 16 as the perforations, 50 are now covered by flouid drug 7s. The perforations 50 realst air ingress because of the surface tarrison of the flouid drug forming memical across the perforations 50 in the perforate portion 27 and therefore, as 30 the chambers V1 and V2 expand, the pressures within those chambers decrease below emblent pressure. The reservoir body 2 continues to move upwards 2a until the restoring force of the main return spring 5 is stalled by the opposing forces created, in the main, by the negative pressures in the chambers V1 and V2 and by the tension in the elastiomeric diaptragm 15.

When the damping valve 19 is fully closed, no air can enter the chamber V1 and so the main return spring 5 will not extend far before it is stalled by the negative

D 02/30207 PCT/GB01/04964

The maximum spring load of the plunger return spring 10 preferably should not exceed 20N. This therefore limits the force that a user must exert in order to operate the

The plunger return spring 10 is preloaded and this preload should be greater than
the fully compressed load in the main return spring 5. This ensures that the reservoir
body 2 is fully down against its physical stop 28 before the dose is metered into the
hotding reservoir 18. If the dose is metered from the dispersing aperture 14 when the
reservoir body 2 is not fully down, all or part of the dose my miss the holding reservoir
18. The terget negative pressure in the chamber V2 will then not be reached when the
cap 8 is released because the perforations in the perforate portion 27 of the membrane
18 will remain dry and open.

As the plunger 8 is withdrawn 8b from the reservoir cavity 12 a partial vacuum is created between the closed one-way elastomenic ball-valve 13 and the plunger seal 24. The spring force range of the plunger return spring 10 must be sufficient to lift the plunger 8 out of the reservoir cavity 12 when the cop 9 when the cap is released, in order to create a pressure difference across the plunger seal 24 (between the fould drug. 7 in reservoir cavity 6 and the elastomenic ball valve 13) which exceeds the sealing pressure of the plunger seal 24 against the side-wall 12a of the reservoir cavity 12. Liquid drug 7 is then above to flow past the plunger seal 24 and into the reservoir cavity 12 as the plunger 8 is withdrawn 8b. This has the advantage of minimizing fournementation within the reservoir cavity 12 especially with flould drugs containing sunfactionies as part of their formutation.

The spring force range of the mash return spring 5 must be sufficient to lift the reservoir body 2 against the negative pressures generated within the chambers V1,V2, the stretching of the elastiomeric disphragm 15 and the triction of the sliding seedbetween the reservoir body 2 and the casing 1.

- The maximum brision in the etastomeric displayagm 15, which is achieved when the reservoir body 2 is at rest, must be high enough to maintain the target negative pressure within the chamber V2 without the etastomeric displayagm 15 deforming under 30 that negative pressure. This tresioned torce must not be high enough to prevent the main return spring 5 from fitting the reservoir body 2 up against the predetermined physical stop during the generation of the negative pressures.

to summary, the extension force of the plunger return spring 10 is greater than the extension torce of the main return spring 5 which is greater than the tensioned torce of the elastomeric diagrangem 15.

From Fig. 7, it can be seen that the control circuit employs two operational amplifiers (op-amps) 31, 32, which can supply output voltages over the full power supply

25

25

range, i.e. between the supply voltage Voc and ground GND. Op-amp 31 is in closed loop configuration with a Wheatstone bridge to maintain a constant resistance of the enemometer fizzment 39. The drive voltage 40 for the Wheatstone bridge is supplied to the op-emp 32 which is configured as a voltage comparator. The comparator is a 5 switching device having a measurement input and a reference input. When the measurement voltage 33 is higher than the reference voltage 34, the output 35 from the .ap-amp 32 switches from GND to Voc.

· Circuits of this type are well known in enemometry. However the circuit of Fig. 7 shows a simple implementation of a circuit which can discriminate between high and 10 low rates of change of air flow. The RC time constant used for the reference voltage 34 is set so that it can respond, in a damped manner, to slowly varying conditions such as changes in ambient conditions and to the normal slow breathing of a patient. Therefore, the reference voltage 34 is insensitive to fast rates of change in air flow during the patient inhabition cycle. The measurement voltage 33 at the comparator opemp 32 is an attenuated signal from the Wheatstone bridge drive voltage 40, but does not have a long time constant filter and so reads directly with the patient's tribalistion.

. If the patient inhales at a sufficiently high volume rate, then the measurement voltage 33 will exceed the reference voltage 34 due to the difference in the time constant of the reference and measurement voltages. In order for this to happen, a certain threshold of rate of change of air flow must be exceeded. When the measurement voltage 33 exceeds the reference voltage input 34, there will be a change in the voltage state at the output 35. Since the comparator circuit does not have any feedback, it is operating the high gain mode and so has only two output states, 0v and Voc. Thus, it is possible to couple this circuit directly to TTL logic devices.

Two variable resistors 36, 37 are provided within the control circuit 30. The variable resistor 38 in the comparator is used to edjust the level of attenuation applied to the measurement voltage \$3, which sets the sensitivity of the circuit to the rate of change of patient's inhatation. The second variable resistor 37, in the Wheststone bridge, is provided to set the temperature of the anemometer filament 39 and is used $\cdot\cdot$ to set the minimum rate of change of air flow that the circuit can detect. Thus, these. adjustments allow a high degree of flexibility in the installation of the anemometer as a breath trigger davice.

A field effect transistor 38 is used to effer the reference ratio of the Wheekstone bridge thus enabling or disabiling the air flow sensor via "ENABLE". In this way, the . power consumption of the control circuit 30 is reduced, allowing the device to have a useful operating life when powered by batteries.

PCT/GB01/04964 WO 02/38207

CLAUMS

An aerosol drug dispensing device in which a metered dose of a acologically active liquid is provided to a holding reservoir from which the dose is 5 - then dispensed as an earosol spray, the holding reservoir including a perforate membrane from which the dose is dispensed by actuation of the perforate membrane to cause liquid flow through the perforate membrane, the perforate membrane having perforations having a reverse taper, namely a larger cross-sectional area at that face of the membrane away from which liquid droplets emerge than at the opposite face of the membrane, characterised in that:

the holding reservoir is disposed in a chamber having a movable surface in the form of a resilient diaphragm, which is stretchable to vary the volume of, and thus adjust the pressure in, the chamber to provide a pressure differential across the resilient disphragm during actuation of the perforate membrane such that the pressure within the holding reservoir is less than the ambient pressure on the opposite side of the perforate

a control device is arranged to control the stretching of the resillent diaphragm and thus the generation of the differential pressure across the perforate membrane.


- An aerosol drug dispensing device according to claim 1, wherein the resilient displaym is formed from an elastomeric material.
 - An aerosol drug dispensing device according to daim 2, wherein the elastomenic material is nubber.
 - An eerosol drug dispensing device according to any of claims 1 to 3, wherein the chamber contains one or more valves for controlling the inlet and/or outlet of Builds from the chamber.
- An aerosol drug dispensing device according to any of cizims 1 to 4, wherein the control device is a radiprocating plunger which is connected to the resilient diaphyagm substantially at the centre.
- 6. An aerosol drug dispensing devices according to any of claims 1 to 5, wherein the resilient disphragm is damped by a spray head assembly substantially at its outer edge.

Figure 8a shows cross-sectional detail of a first example perforate membrane 16. which is operable to vibrate substantially in the direction of arrow 58 and which is suitable for use with the drug dispensing device 25 to produce fine eerosol aprays. In one embodiment, the membrane 15 comprises a circular layer of polymer which contains a pturality of tapered conical perforations 50. Each perforation 50 has openings 53 in the front exit tace and openings 54 in the rear entry tace, which perforations are taid out in a square lattice. Such perforations may be introduced into polymer membranes by, for example, leser-drilling with an excimer laser.

Figure 8b shows cross-sectional detail of a second example perforate membrane . 2016, which membrane is operable to vibrate substantially and suitable for use with drug dispensing device 25 in the direction of arrow 58. The membrane is formed as a circular disc of diameter 8mm from electroformed nickel, and is manufactured, for example, by Stork Veco of Eerbeek, The Netherlands. Its thickness is 70 microns and is formed with a plurelity of perforations shown at 2050 which, at 'tront' face 2051, are of diameter shown at "a" of 120 microns and at "rear" face 2052 are of diameter shown at "b" of 30 microns. The perforations are tast out in an equilateral triangular lattice of pitch 170 µm: The profile of the perforations varies smoothly between the front and rear face diameters through the membrane thickness with substantially first fand regions (shown at "c") of smallest dimension 50 µm in front face 2051.

WO 02/38207

An aerosol drug dispensing device according to any of claims 1 to 6, including a sealing means to ensure that there is no fluid flow past the resilient disphragm.






Figure 2





Figure 3






Figure 5







Figure 6







	INTERNATIONAL SEARCH RE	PORT	PCT/68 OL	/04964	
IPC 7	A51H15/00 805911/00				
	n kalamatansi Palam Quantinalan (PC) ur ka lada nadamat ebasilik: 1804/1983)	ates and PC			
N PORTO	المراوية في ومحوا منون منوروسيان إمارية المراوية المراوية	-			
IPC 7	A61N 805B				
1	and security also has change purposed than to be extend that				
(barrie	ما كان أو جميع فاحدد أسباع بطاعاً جنا وشدة اطبيعت ميماً عليا	بالجادر ومقب يلين هو	-		
EPO-In	ternal, MPI Data, PAJ				
C. DOCUM	EDITS CONSCIENTED TO BE RELEVANT				
CHILDY.	Chicas or decimal, with inclusion, where appropriate, of the col	Print branchi		Project to come No.	
A	MO 95 15822 A (KUMBERSTONE VICTO: ;SANT ANDREW JONATHAN (GB); TECH 15 June 1995 (1995-06-15) cited in the application	R CAREY MOLOGY PA)		1	
A	bbstrect US 5 758 637 A (1VRI YEHUDA ET / 2 June 1998 (1998-05-02)	AL)		1	
	abstract column 15, line 5 -column 17, lif figures 13-16	ne 5;			
^	US 4 702 418 A (CARTER ROBERT E 27 October 1987 (1987-10-27) abstract	ET AL)		1	
		-/			
1	1				
☑~	the description on hind is the confession of the C.	☑ ~		>	
	alogoriles of cloud decembers; read classified the present state of the seat which is not classed in the of placement relations;	T to describe po or private data or class to excession	وم موادمون من المواون ويد موادمون من الماري ويد موادمون	emiteral City Cale See application had any orders had	
1- =	izarni iz bi al palitzioj na minerio Gazanni izi politzioj na minerio bizantisti din	7 (000)		-	
V ===					
Concept which may have dead on printing compily or which in the container in them dead with the printing of the dead within the production of a dead with the container in the container in the dead within the dead with					
the reason of this is to be broadened that the but					
	have then the partiest of the sales facility				
-	25 February 2002	04/03/	2002	arth report	
	couling actions of the GA	Addression of State			
	Empenin Parm Chin, P.B. Ship Patenthan S (4, - 520) (4) Specia 74 (4) - 72 34 - 550, 71 37 251 ato si Par (471-78) 86-6718	Mielse	n, M '	•	

page 1 of 2

DY	TERNA	TIONAL SEARCH	1 REPOF	t T	PCT/GB	01/04964
Patent document chief in exect) report		Pu <u>ddischin</u> Clare		Palaci terib meriber(X)		Publication date
WO 9515822	A	15-05-1995	AT AU	1716! 6871:		15-10-1998 19-02-1998
			AU AU	119599		27-06-1995
			BR	940821	11 A	17-12-1996
			Ċ	217657 960164		15-06-1995 17-09-1997
			DE	6941370		05-11-1998
			DE	6941370		25-02-1999
			ĐΚ	73297 073297		21-06-1999 25-09-1996
			EP ES	21232		01-01-1999
			WO	951582	2 A1	15-06-1995
			JP US	1050257 582347		10-03-1998 20-10-1998
			us_	30234	(A A	20-10-1990
US 5758637	A	02-06-1998	US	55865		24-12-1995
			ΑIJ	7110		07-10-1999 19-03-1997
			AU Br	701009 96066		30-09-1997
			CA	22039	6 A1	06-03-1997
			EP	07948		17-09-1997 18-08-1998
			JP -US	1050825 60857		11-07-2000
			¥ŏ	97078		06-03-1997
US 4702418	A	27-10-1987	HOKE			
US 6062212	A	15-05-2000	69	22723	29 A	18-05-1994
***************************************		••	ÄÜ	6703		11-07-1995
			AU CA	53418 21447		24-05-1994 11-05-1994
			ČŘ	11010	MA.B	05-04-1995
			ÐĒ	693169	29 01	19-03-1998
			DE EP	693159 06825		20-08-1998 22-11-1995
			ËS	21130		16-04-1998
			FI	9514	20 A	29-03-1995
			80	94099		11-05-1994 25-12-2001
			JP JP	32417 85026		26-03-1996
			£R	2642		16-08-2000
EP (54272)	A	19-05-1993	AT	934		15-09-1993
	-		EP	05427		19-05-1993 26-06-1996
			EP AT	07180 1432		15-10-1996
			ΑŤ	1945	13 T	15-07-2000
			ΑIJ	6376		03-06-1993
			AU B2	67897 90062	AU A	23-07-1992 24-09-1991
			ä	20319		13-06-1991
•		. •	ĊH	10549	16 A ,B	02-10-1991
			DE DE	690029 690287		30-09-1993 31-10-1996
			Œ	690335		17-03-2000
			Œ	590335	11 T2	23-11-2000
			CK.		22 T3	10-01-1994 03-03-1997
		•	DK.	342/	23 73	25-05-1331

	INTERNATIONAL SEARCH REPORT PCT/68 01/				
CEC	COMPANY DESCRIPTION OF THE PROPERTY OF THE PRO				
-	Country of Sections, with Indication, where appropriate, of the relevant passages		Platering in 1869 Ms.		
^	US 6 062 212 A (BARMES PAUL ET AL) 16 May 2000 (2000-05-16) abstract		1		
^	EP 0 542 723 A (BESPAK PLC) 19 May 1993 (1993-05-19) abstract		1		
À	US 5 823 434 A (COOPER GUY F) 20 October 1990 (1998-10-20) abstract		1		

page 2 of

Palent descript		Publication Page		Patent Date(ly	01/04964 Petertra
CORD IN COMMENT PROPERTY				mander(2)	data
EP 0542723	A		EP	0432992 A1	19-06-199
			ES	2030348 A5	16-10-199
			ES ES	2043293 T3 2092146 T3	16-12-1993 16-11-1993
			FI	906089 A	13-06-199
			FI	931780 A	20-04-199
			FR	2655572 A1	14-06-199
			6B 6B	2240494 A .8 2253076 A .B	07-08-199 14-07-199
			ĨĔ	904468 A1	19-06-199
			iī	96597 A	12-04-199
			17	1244181 B	08-07-199
			JP.	1917114 C	23-03-199
			JP JP	4100557 A 6040984 B	02-04-199: 01-06-199:
			KR	152086 81	01-10-199
			PCX	172730 B	10-01-199
			NO	179275 B	03-06-199
			NZ PT	236418 A 96169 A ,B	23-12-199: 31-08-199:
			en en	2051756 C1	10-01-199
			ÜS	5152456 A	06-10-199
			us	5261601 A	16-11-199
			ZA	9009776 A	26-08-199
US 5823434	A	20-10-1998	US	5938118 A	17-08-199

page 1 of 2